Filtered By:
Condition: Diabetes
Drug: Aspirin
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 378 results found since Jan 2013.
Sex Differences in Outcomes of Ticagrelor Therapy With or Without Aspirin After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Secondary Analysis of the TICO Randomized Clinical Trial
CONCLUSIONS: After percutaneous coronary intervention for acute coronary syndrome, women demonstrated worse clinical outcomes than men. Ticagrelor monotherapy after 3-month dual-antiplatelet therapy was associated with significantly lower risk of net adverse clinical events in women without sex interaction.PMID:37021576 | DOI:10.1161/ATVBAHA.122.318725
Source: Arteriosclerosis, Thrombosis and Vascular Biology - April 6, 2023 Category: Cardiology Authors: Bom Lee Seung-Jun Lee Byeong-Keuk Kim Yong-Joon Lee Sung-Jin Hong Chul-Min Ahn Jung-Sun Kim Young-Guk Ko Donghoon Choi Meyong-Ki Hong Yangsoo Jang Source Type: research
Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
ConclusionsWithout increasing bleeding and statin-associated adverse events, intensive rosuvastatin therapy plus 7-day DAPT significantly reduced the risk of recurrent stroke, especially for subgroups with high-risk factors.Clinical trial registration. China Clinical Trial Registration Center (ChiCTR1800017809).
Source: European Journal of Clinical Pharmacology - March 1, 2023 Category: Drugs & Pharmacology Source Type: research
Does aspirin have a place in primary cardiovascular prevention by the polypill ? Simulation study on a realistic virtual population
CONCLUSION: Until proven otherwise, aspirin has only a limited place in individuals between 35 and 65 years without a cardiovascular history. We showed how simulating therapeutic strategies on a realistic virtual population could be used for best applying available evidence.PMID:36841655 | DOI:10.1016/j.therap.2023.01.011
Source: Therapie - February 25, 2023 Category: Psychiatry & Psychology Authors: Mor Fall Guillaume Grenet Hai-Ha Le Behrouz Kassa ï Jean-Christophe Lega R émy Boussageon Sabine Mainbourg Ivanny Marchant Johanne Gafsi Amadou Moctar Dieye Fran çois Gueyffier Source Type: research
Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial
Conclusions. In REWIND, most women met clinically relevant treatment targets, but in lower proportions than men. Women had a lower risk for all cardiovascular outcomes except stroke. Clinical trials.gov registration number: NCT01394952.PMID:36723445 | DOI:10.1080/14017431.2023.2166101
Source: Scandinavian Cardiovascular Journal - February 1, 2023 Category: Cardiology Authors: Giulia Ferrannini Juan M Maldonado Sohini Raha Purnima Rao-Melacini Rutaba Khatun Charles Atisso Linda Shurzinske Hertzel C Gerstein Lars Ryd én M Angelyn Bethel Source Type: research
Acetylsalicylic Acid (aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
CONCLUSION: Aspirin use in patients with DM reduces the composite endpoint of CV death, non-fatal MI and stroke compared with a placebo. However, routine use of aspirin for primary prevention among diabetic patients cannot be advised due to the increased risk of major bleeding. These findings suggest careful risk assessment of individual patients.PMID:36718966 | DOI:10.2174/1570161121666230131120544
Source: Current Vascular Pharmacology - January 31, 2023 Category: Drugs & Pharmacology Authors: Shuangbo Liu Janine Eckstein Anna Lam Asim Cheema Source Type: research
Aspirin in diabetic patients at primary prevention: insights of the VITAL cohort
ConclusionsThe VITAL data confirmed diabetes as an important risk factor for cardiovascular events in a contemporary cohort but did not show cardiovascular benefits of aspirin in primary prevention among people with diabetes who were shown to be at higher risk of cardiovascular events.
Source: Journal of Endocrinological Investigation - January 18, 2023 Category: Endocrinology Source Type: research
